Abstract: Methods and apparatuses are provided for centralized radio access network (CRAN) scalability. In one embodiment, a network node includes processing circuitry configured to cause the network node to schedule at least one wireless device according to a radio resource partition, the radio resource partition representing a division of radio resources between at least two schedulers of a same cell, and each radio resource partition of the cell being assigned to a corresponding scheduler of the at least two schedulers; and receive, from at least one scheduler of the at least two schedulers, an indication of an amount of the radio resources that are scheduled by the at least one scheduler. In one embodiment, a network node includes processing circuitry configured to cause the network node to send, to a master scheduler, an indication of an amount of the radio resources that are scheduled by the network node.

Abstract: Systems and methods are disclosed for cleaning and sterilizing fluids and other materials. In one implementation, one or more emitters are submerged within a fluid and emit electromagnetic waves having a variable frequency. The frequency of the electromagnetic waves is swept across a frequency range to neutralize bacteria, viruses, and other pathogens in the fluid. The emitters may be submerged within a fluid reservoir and/or within the interior of an enclosed fluidic path (e.g., a pipe). Solid materials may be sterilized by immersing the solid materials within the fluid of such a fluid reservoir. In another implementation, electromagnetic waves may be applied to one or more wires that are wrapped around an exterior wall of a pipe. The frequency of the electromagnetic waves may be varied across a frequency range, resulting in scale and other materials being cleaned from the interior wall of the pipe.

Abstract: According to one or more embodiments, a first network node of a first radio access technology, RAT, configured to communicate with a second network node of a second RAT different from the first RAT is provided. The first network node includes processing circuitry configured to: schedule a physical resource block, PRB, in a predetermined frequency carrier range where the scheduling starts from a predefined frequency location in the predetermined frequency carrier range, receive an indication that the PRB has been scheduled by the second network node, and responsive to the received indication, discard the PRB scheduled by the first network node if the PRB is located outside of a first predetermined partition of radio resources allocated to the first network node.

Abstract: Systems and methods are disclosed for cleaning and sterilizing fluids and other materials. In one implementation, one or more emitters are submerged within a fluid and emit electromagnetic waves having a variable frequency. The frequency of the electromagnetic waves is swept across a frequency range to neutralize bacteria, viruses, and other pathogens in the fluid. The emitters may be submerged within a fluid reservoir and/or within the interior of an enclosed fluidic path (e.g., a pipe). Solid materials may be sterilized by immersing the solid materials within the fluid of such a fluid reservoir. In another implementation, electromagnetic waves may be applied to one or more wires that are wrapped around an exterior wall of a pipe. The frequency of the electromagnetic waves may be varied across a frequency range, resulting in scale and other materials being cleaned from the interior wall of the pipe.

Abstract: An extended release oral dosage form comprising as active substance tacrolimus or a pharmaceutically active analogue thereof for a once daily immunosuppressive treatment of a patient in need thereof, preferable a kidney or liver transplant patient. The dosage form releases the active substance over an extended period of time. It also provides improved pharmacokinetic parameters due to an extended and constant in vivo release including substantial decreased peak concentrations, despite increased bioavailability, substantial extended times for maximal concentration, and higher minimal concentrations when compared with conventional immediate release dosage forms and a recent modified release tacrolimus dosage form.

Abstract: An extended release oral dosage form comprising as active substance tacrolimus or a pharmaceutically active analogue thereof for a once daily immunosuppressive treatment of a patient in need thereof, preferable a kidney or liver transplant patient. The dosage form releases the active substance over an extended period of time. It also provides improved pharmacokinetic parameters due to an extended and constant in vivo release including substantial decreased peak concentrations, despite increased bioavailability, substantial extended times for maximal concentration, and higher minimal concentrations when compared with conventional immediate release dosage forms and a recent modified release tacrolimus dosage form.

Abstract: An extended release oral dosage form comprising as active substance tacrolimus or a pharmaceutically active analogue thereof for a once daily immunosuppressive treatment of a patient in need thereof, preferable a kidney or liver transplant patient. The dosage form releases the active substance over an extended period of time. It also provides improved pharmacokinetic parameters due to an extended and constant in vivo release including substantial decreased peak concentrations, despite increased bioavailability, substantial extended times for maximal concentration, and higher minimal concentrations when compared with conventional immediate release dosage forms and a recent modified release tacrolimus dosage form.

Abstract: A modified release composition comprising tacrolimus releases less than 20% w/w of the active ingredient within 0.5 hours when subjected to an in vitro dissolution test using USP Paddle method and using 0.1 N HCl as dissolution medium and has increased bioavailability by effectively reducing or even avoiding the effects of CYP3A4 metabolism. The modified composition may be coated with an enteric coating; and/or may comprise a solid dispersion or a solid solution of tacrolimus in a hydrophilic or water-miscible vehicle and one or more modifying release agents; and/or may comprise a solid dispersion or a solid solution of tacrolimus in an amphiphilic or hydrophobic vehicle and optionally one or more modifying release agents.

Abstract: An extended release oral dosage form comprising as active substance tacrolimus or a pharmaceutically active analogue thereof for a once daily immunosuppressive treatment of a patient in need thereof, preferable a kidney or liver transplant patient. The dosage form releases the active substance over an extended period of time. It also provides improved pharmacokinetic parameters due to an extended and constant in vivo release including substantial decreased peak concentrations, despite increased bioavailability, substantial extended times for maximal concentration, and higher minimal concentrations when compared with conventional immediate release dosage forms and a recent modified release tacrolimus dosage form.

Abstract: An extended release oral dosage form comprising as active substance tacrolimus or a pharmaceutically active analogue thereof for a once daily immunosuppressive treatment of a patient in need thereof, preferable a kidney or liver transplant patient. The dosage form releases the active substance over an extended period of time. It also provides improved pharmacokinetic parameters due to an extended and constant in vivo release including substantial decreased peak concentrations, despite increased bioavailability, substantial extended times for maximal concentration, and higher minimal concentrations when compared with conventional immediate release dosage forms and a recent modified release tacrolimus dosage form.

Abstract: An extended release oral dosage form comprising as active substance tacrolimus or a pharmaceutically active analogue thereof for a once daily immunosuppressive treatment of a patient in need thereof, preferable a kidney or liver transplant patient. The dosage form releases the active substance over an extended period of time. It also provides improved pharmacokinetic parameters due to an extended and constant in vivo release including substantial decreased peak concentrations, despite increased bioavailability, substantial extended times for maximal concentration, and higher minimal concentrations when compared with conventional immediate release dosage forms and a recent modified release tacrolimus dosage form.

Abstract: Systems and methods are disclosed for cleaning and sterilizing fluids and other materials. In one implementation, one or more emitters are submerged within a fluid and emit electromagnetic waves having a variable frequency. The frequency of the electromagnetic waves is swept across a frequency range to neutralize bacteria, viruses, and other pathogens in the fluid. The emitters may be submerged within a fluid reservoir and/or within the interior of an enclosed fluidic path (e.g., a pipe). Solid materials may be sterilized by immersing the solid materials within the fluid of such a fluid reservoir. In another implementation, electromagnetic waves may be applied to one or more wires that are wrapped around an exterior wall of a pipe. The frequency of the electromagnetic waves may be varied across a frequency range, resulting in scale and other materials being cleaned from the interior wall of the pipe.

Abstract: A modified release composition comprising tacrolimus releases less than 20% w/w of the active ingredient within 0.5 hours when subjected to an in vitro dissolution test using USP Paddle method and using 0.1 N HCl as dissolution medium and has increased bioavailability by effectively reducing or even avoiding the effects of CYP3A4 metabolism. The modified composition may be coated with an enteric coating; and/or may comprise a solid dispersion or a solid solution of tacrolimus in a hydrophilic or water-miscible vehicle and one or more modifying release agents; and/or may comprise a solid dispersion or a solid solution of tacrolimus in an amphiphilic or hydrophobic vehicle and optionally one or more modifying release agents.

Abstract: A modified release composition comprising tacrolimus releases less than 20% w/w of the active ingredient within 0.5 hours when subjected to an in vitro dissolution test using USP Paddle method and using 0.1 N HCl as dissolution medium and has increased bioavailability by effectively reducing or even avoiding the effects of CYP3A4 metabolism. The modified composition may be coated with an enteric coating; and/or may comprise a solid dispersion or a solid solution of tacrolimus in a hydrophilic or water-miscible vehicle and one or more modifying release agents; and/or may comprise a solid dispersion or a solid solution of tacrolimus in an amphiphilic or hydrophobic vehicle and optionally one or more modifying release agents.

Abstract: An extended release oral dosage form comprising as active substance tacrolimus or a pharmaceutically active analogue thereof for a once daily immunosuppressive treatment of a patient in need thereof, preferable a kidney or liver transplant patient. The dosage form releases the active substance over an extended period of time. It also provides improved pharmacokinetic parameters due to an extended and constant in vivo release including substantial decreased peak concentrations, despite increased bioavailability, substantial extended times for maximal concentration, and higher minimal concentrations when compared with conventional immediate release dosage forms and a recent modified release tacrolimus dosage form.

Abstract: A modified release composition comprising tacrolimus releases less than 20% w/w of the active ingredient within 0.5 hours when subjected to an in vitro dissolution test using USP Paddle method and using 0.1 N HCl as dissolution medium and has increased bioavailability by effectively reducing or even avoiding the effects of CYP3A4 metabolism. The modified composition may be coated with an enteric coating; and/or may comprise a solid dispersion or a solid solution of tacrolimus in a hydrophilic or water-miscible vehicle and one or more modifying release agents; and/or may comprise a solid dispersion or a solid solution of tacrolimus in an amphiphilic or hydrophobic vehicle and optionally one or more modifying release agents.

Abstract: Stable tablets and pharmaceutical compositions in particulate form comprising a fibrate, for example fenofibrate, dissolved or dispersed in an non-aqueous vehicle with improved bioavailability, thereby eliminating the food effect so that the tablet or composition can be administered to a patient irrespective of being in fed or fasted state.

Abstract: A modified release composition comprising tacrolimus which is useful for the treatment or prevention of rejection reactions by transplantation of organs or tissues.

Abstract: A modified release composition comprising tacrolimus releases less than 20% w/w of the active ingredient within 0.5 hours when subjected to an in vitro dissolution test using USP Paddle method and using 0.1 N HCl as dissolution medium and has increased bioavailability by effectively reducing or even avoiding the effects of CYP3A4 metabolism. The modified composition may be coated with an enteric coating; and/or may comprise a solid dispersion or a solid solution of tacrolimus in a hydrophilic or water-miscible vehicle and one or more modifying release agents; and/or may comprise a solid dispersion or a solid solution of tacrolimus in an amphiphilic or hydrophobic vehicle and optionally one or more modifying release agents.

Abstract: A modified release composition comprising tacrolimus which is useful for the treatment or prevention of rejection reactions by transplantation of organs or tissues.